Dr. Landgren on Maintenance Therapy in Myeloma

C. Ola Landgren, MD, PhD
Published: Monday, Feb 25, 2013

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the pros and cons of maintenance therapy for patients with myeloma.

Maintenance therapy in myeloma, Landgren says, is not new, as studies have analyzed steroids, interferon, thalidomide, lenalidomide, and proteasome inhibitors. Several studies have demonstrated progression-free survival advantage with maintenance therapy.

One study, with lenalidomide, showed overall survival advantage but also severe side effects. Patients treated with lenalidomide had an increased risk of developing a secondary hematologic malignancy than with placebo, though the risk was not great. Though lenalidomide can provide overall survival advantage, a secondary hematologic malignancy would be devastating to a patient.
 
Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the pros and cons of maintenance therapy for patients with myeloma.

Maintenance therapy in myeloma, Landgren says, is not new, as studies have analyzed steroids, interferon, thalidomide, lenalidomide, and proteasome inhibitors. Several studies have demonstrated progression-free survival advantage with maintenance therapy.

One study, with lenalidomide, showed overall survival advantage but also severe side effects. Patients treated with lenalidomide had an increased risk of developing a secondary hematologic malignancy than with placebo, though the risk was not great. Though lenalidomide can provide overall survival advantage, a secondary hematologic malignancy would be devastating to a patient.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Expert Insights on the Management of Myeloproliferative Neoplasms: Evidence-based Approaches and Emerging Strategies to Address Challenges in CareSep 29, 20181.5
1st Annual LIVE Medical Crossfire®: Expert Exchanges in Hematologic Malignancies OnlineSep 30, 20188.0
Publication Bottom Border
Border Publication
x